| 2025-12-08 |
详情>>
内部人交易：
Kalia Kumud等共交易6笔
|
| 2025-11-06 |
详情>>
股本变动：
变动后总股本12937.44万股
变动原因 ▼▲
- 原因：
- Common Stock offered 3,333,333 shares by the company
|
| 2025-10-29 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-2.32美元,归母净利润-2.88亿美元,同比去年增长11.55%
|
| 2025-10-29 |
财报披露：
美东时间 2025-10-29 盘后发布财报
|
| 2025-07-30 |
详情>>
业绩披露：
2025年中报每股收益-1.57美元,归母净利润-1.95亿美元,同比去年增长10.36%
|
| 2025-04-30 |
详情>>
业绩披露：
2025年一季报每股收益-0.77美元,归母净利润-9515.9万美元,同比去年增长17.24%
|
| 2025-04-29 |
股东大会：
将于2025-06-18召开股东大会
会议内容 ▼▲
- 1.To elect the four Class I director nominees to serve on the Board of Directors of Guardant Health, Inc. for a three-year term expiring at the 2028 annual meeting of stockholders or until their successors have been elected and qualified. The four nominees for election to the Board of Directors are Vijaya Gadde, Roberto Mignone, Myrtle Potter and Musa Tariq;
2.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025;
3.To approve, on a non-binding advisory basis, the compensation of our named executive officers, as described in the “Compensation Discussion and Analysis,” executive compensation tables and accompanying narrative disclosures in our proxy materials;
4.To consider and take action upon such other matters as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2025-02-20 |
详情>>
业绩披露：
2024年年报每股收益-3.56美元,归母净利润-4.36亿美元,同比去年增长8.98%
|
| 2025-02-20 |
详情>>
业绩披露：
2022年年报每股收益-6.41美元,归母净利润-6.55亿美元,同比去年增长-61.36%
|
| 2024-11-06 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-2.66美元,归母净利润-3.25亿美元,同比去年增长-11.27%
|
| 2024-08-07 |
详情>>
业绩披露：
2023年中报每股收益-1.95美元,归母净利润-2.06亿美元,同比去年增长41.50%
|
| 2024-08-07 |
详情>>
业绩披露：
2024年中报每股收益-1.78美元,归母净利润-2.18亿美元,同比去年增长-5.48%
|
| 2024-05-23 |
复牌提示：
2024-05-23 06:55:00 停牌，复牌日期 2024-05-24 07:10:00
|
| 2024-05-09 |
详情>>
业绩披露：
2024年一季报每股收益-0.94美元,归母净利润-1.15亿美元,同比去年增长13.89%
|
| 2024-04-25 |
股东大会：
将于2024-06-12召开股东大会
会议内容 ▼▲
- 1.To elect the three Class III director nominees to serve on the Board of Directors of Guardant Health, Inc. for a three-year term expiring at the 2027 annual meeting of stockholders or until their successors have been elected and qualified. The three nominees for election to the Board of Directors are Helmy Eltoukhy, Steve Krognes and AmirAli Talasaz;
2.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024;
3.To approve, on a non-binding advisory basis, the compensation of our named executive officers, as described in the “Compensation Discussion and Analysis,” executive compensation tables and accompanying narrative disclosures in our proxy materials;
4.To consider and take action upon such other matters as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2024-02-22 |
详情>>
业绩披露：
2023年年报每股收益-4.28美元,归母净利润-4.79亿美元,同比去年增长26.76%
|
| 2023-11-06 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-2.66美元,归母净利润-2.92亿美元,同比去年增长43.18%
|
| 2023-04-27 |
股东大会：
将于2023-06-14召开股东大会
会议内容 ▼▲
- 1.To elect the three Class II director nominees to serve on the Board of Directors of Guardant Health, Inc. for a three-year term expiring at the 2026 annual meeting of stockholders or until their successors have been elected and qualified. The three nominees for election to the Board of Directors are Ian Clark, Meghan Joyce and Samir Kaul;
2.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2023;
3.To approve, on a non-binding advisory basis, the compensation of our named executive officers, as described in the “Compensation Discussion and Analysis,” executive compensation tables and accompanying narrative disclosures in our proxy materials;
4.To consider and take action upon such other matters as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2022-04-28 |
股东大会：
将于2022-06-15召开股东大会
会议内容 ▼▲
- 1.To elect the two Class I director nominees to serve on the Board of Directors of Guardant Health, Inc. for a three-year term expiring at the 2025 annual meeting of stockholders or until their successors have been elected and qualified. The two nominees for election to the Board of Directors are Vijaya Gadde and Myrtle Potter;
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2022;
3.To approve, on a non-binding advisory basis, the compensation of our named executive officers, as described in the “Compensation Discussion and Analysis,” executive compensation tables and accompanying narrative disclosures in our proxy materials;
4.To consider and take action upon such other matters as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-29 |
股东大会：
将于2021-06-16召开股东大会
会议内容 ▼▲
- 1.To elect the three Class III director nominees to serve on the Board of Directors of Guardant Health, Inc. for a three-year term expiring at the 2024 annual meeting of stockholders or until their successors have been elected and qualified. The three nominees for election to the Board of Directors are Helmy Eltoukhy, AmirAli Talasaz and Bahija Jallal;
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2021;
3.To approve, on a non-binding advisory basis, the compensation of our named executive officers, as described in the “Compensation Discussion and Analysis,” executive compensation tables and accompanying narrative disclosures in our proxy materials;
4.To consider and take action upon such other matters as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2020-04-28 |
股东大会：
将于2020-06-12召开股东大会
会议内容 ▼▲
- 1.To elect two Class II director nominees to serve on the Board of Directors of Guardant Health, Inc. for a three-year term expiring at the 2023 annual meeting of stockholders. The two nominees for election to the Board of Directors are Ian Clark and Samir Kaul;
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2020;
3.To approve, on an advisory (non-binding) basis, the frequency of future stockholder advisory votes regarding the compensation of our named executive officers, or say-on-pay votes;
4.To conduct any other business properly brought before the meeting.
|
| 2019-04-29 |
股东大会：
将于2019-06-18召开股东大会
会议内容 ▼▲
- 1.To elect two Class I director nominees to serve on the Board of Directors of Guardant Health, Inc. for a three-year term expiring at the 2022 annual meeting of stockholders. The two nominees for election to the Board of Directors are Aaref Hilaly and Stanley Meresman;
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2019;
3.To conduct any other business properly brought before the meeting.
|